| Completed | To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants Healthy, Volunteer | Phase 1 | 2025-12-15 |
| Active Not Recruiting | To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Partic Healthy | Phase 1 | 2025-10-27 |
| Recruiting | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Desmoid Tumor, Aggressive Fibromatosis | Phase 4 | 2025-09-17 |
| Completed | Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat Healthy | Phase 1 | 2025-08-21 |
| Active Not Recruiting | A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Desmoid Tumor, Aggressive Fibromatosis | Phase 2 | 2025-08-08 |
| Recruiting | Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib Healthy, Hepatic Impairment | Phase 1 | 2025-05-07 |
| Recruiting | SW-682 in Advanced Solid Tumors Advanced Solid Tumor, Mesothelioma, Malignant | Phase 1 | 2024-07-30 |
| Terminated | Mirdametinib + BGB-3245 in Advanced Solid Tumors Advanced Solid Tumor | Phase 1 / Phase 2 | 2023-02-03 |
| Completed | Nirogacestat in Ovarian Granulosa Cell Tumors Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer | Phase 2 | 2022-08-30 |
| Active Not Recruiting | MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofi Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1) | Phase 2 | 2019-09-29 |
| Completed | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Desmoid Tumor, Aggressive Fibromatosis | Phase 3 | 2019-04-17 |
| Available | Individual Patient Compassionate Use of Mirdametinib Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, Histiocytic Neoplasm, Other MAP-K Pathway Driven Diseases | — | — |
| Available | Individual Patient Compassionate Use of Nirogacestat Desmoid Tumor, NOTCH Gene Mutation Positive Tumors | — | — |